Detalle Publicación

ARTÍCULO

Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.

Autores: Stewart, A Keith; Rajkumar, S Vincent; Dimopoulos, Meletios A; Masszi, Tamás; Špi¿ka, Ivan; Oriol, Albert; Hájek, Roman; Rosiñol, Laura; Siegel, David S; Mihaylov, Georgi G; Goranova Marinova, Vesselina; Rajnics, Péter; Suvorov, Aleksandr; Niesvizky, Ruben; Jakubowiak, Andrzej J; San Miguel Izquierdo, Jesús; Ludwig, Heinz; Wang, Michael; Maisnar, Vladimír; Minarik, Jiri; Bensinger, William I; Mateos, María-Victoria; Ben Yehuda, Dina; Kukreti, Vishal; Zojwalla, Naseem; Tonda, Margaret E; Yang, Xinqun; Xing, Biao; Moreau, Philippe; Palumbo, Antonio; ASPIRE Investigators.
Título de la revista: NEW ENGLAND JOURNAL OF MEDICINE
ISSN: 0028-4793
Volumen: 372
Número: 2
Páginas: 142-152
Fecha de publicación: 2015
Resumen:
In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.
DOI: https://doi.org/ 10.1056/NEJMoa1411321
Impacto:
Google Scholar